Description
3,4-Methylenedioxy Pyrovalerone-
d
8 (hydrochloride) (3,4-MDPV-
d
8 (hydrochloride)) contains eight deuterium atoms at the 1-
pyrrolidinyl position. It is intended for use as an internal standard for the quantification of 3,4-MDPV by GC-
or LC-
mass spectrometry. Pyrovalerone and its analogs are inhibitors of the transporters for certain monoamine neurotransmitters, including dopamine and norepinephrine, preventing their uptake. 3,4-MDPV is an analog of pyrovalerone which includes the 3,4-
methylenedioxy moiety found on 3,4-
methylenedioxymethamphetamine, a DEA Schedule I controlled substance. While its physiological, neurological, and toxicological actions have not been characterized, 3,4-MDPV has been reported by the DEA to be abused as a central nervous system stimulant. Its effective dose and chemical interactions are unknown, but it has been used alone and in combination with other stimulating compounds. Products containing 3,4-MDPV have been marketed in Europe and Australia; they have also been seized by law enforcement in several states. 3,4-MDPV and some of its metabolites have recently been characterized by spectroscopic analysis. 3,4-MDPV is to be used in the forensic analysis of samples that may contain this compound. This product, the hydrochloride salt of 3,4-MDPV, has superior solubility in aqueous solvents, compared to the free base .
Chemical Properties
White Solid
Uses
Labelled Methylenedioxypyrovalerone (M304080) as a central nervous system
Uses
Labelled Methylenedioxypyrovalerone (MDPV; Cat. # M304080) as a central nervous system
References
[1] CATHERINE HéRON Jean J B Jean Costentin. Evidence that pure uptake inhibitors including cocaine interact slowly with the dopamine neuronal carrier[J]. European journal of pharmacology, 1994, 264 3: Pages 391-398. DOI:
10.1016/0014-2999(94)00502-8[2] De Souza, F.I., Zumiotti, A.V., and Da Silva, C.F. Neuregulins 1-α and 1-β on the regeneration the peripheral nerves[J]. Acta Ortop Bras.
[3] FOLKER WESTPHAL . Mass and NMR spectroscopic characterization of 3,4-methylenedioxypyrovalerone: A designer drug with α-pyrrolidinophenone structure[J]. Forensic science international, 2009, 190 1: Pages 1-8. DOI:
10.1016/j.forsciint.2009.05.001[4] MARKUS R. MEYER. Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC–MS and LC–high-resolution MS and its detectability in urine by GC–MS[J]. Journal of Mass Spectrometry, 2010, 45 12: 1426-1442. DOI:
10.1002/jms.1859[5] KINGA FARKAS. [Clinical characteristics of 5 hospitalized 3,4-methylenedioxypyrovalerone (MDPV) users].[J]. Psychiatria Hungarica, 2013, 28 4: 431-439.
[6] SABINA STRANO-ROSSI. Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MPDV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry[J]. Rapid Communications in Mass Spectrometry, 2010, 24 18: 2706-2714. DOI:
10.1002/rcm.4692
